BioWorld

June 17, 2008

View Archived Issues

Acadia Sinks as ACP-104 Misses Endpoint in Schizophrenia Trial

Shares of Acadia Pharmaceuticals Inc. plunged 43 percent Monday on news that its experimental schizophrenia drug, ACP-104, failed to meet its primary endpoint of antipsychotic efficacy in a 247-patient Phase IIb study. (BioWorld Today) Read More

Mpex, GSK in Antibiotics Deal Using Efflux Pump Inhibitors

Read More

'Circuit Neuromics' Championed as Path to Understanding Mood

Read More

Want a Wicked Cool Hat? Try the BioWorld Booth

Read More

Exelixis, FDA Set SPA for XL184 Pivotal Study in Thyroid Cancer

Read More

Other News To Note

Read More

EHA Roundup

Read More

Clinic Roundup

Read More

Financings Roundup

Read More